Wells Fargo & Company Has Lowered Expectations for Danaher (NYSE:DHR) Stock Price

Danaher (NYSE:DHR) had its price objective decreased by research analysts at Wells Fargo & Company from $240.00 to $212.00 in a report released on Wednesday, Marketbeat Ratings reports. The firm currently has an “equal weight” rating on the conglomerate’s stock. Wells Fargo & Company‘s price objective points to a potential upside of 18.62% from the company’s current price.

A number of other research firms have also weighed in on DHR. Jefferies Financial Group reissued a “buy” rating and set a $245.00 target price on shares of Danaher in a report on Tuesday. Weiss Ratings reissued a “hold (c)” rating on shares of Danaher in a report on Friday, March 27th. Rothschild & Co Redburn set a $205.00 target price on shares of Danaher in a report on Friday, April 17th. Robert W. Baird reduced their target price on shares of Danaher from $251.00 to $249.00 and set an “outperform” rating on the stock in a report on Friday, April 17th. Finally, Barclays reduced their target price on shares of Danaher from $250.00 to $230.00 and set an “overweight” rating on the stock in a report on Tuesday, April 14th. Seventeen investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $242.45.

Danaher Trading Down 2.9%

Shares of Danaher stock opened at $178.72 on Wednesday. Danaher has a 1 year low of $175.00 and a 1 year high of $242.80. The company has a current ratio of 1.87, a quick ratio of 1.51 and a debt-to-equity ratio of 0.33. The firm has a market capitalization of $126.49 billion, a PE ratio of 34.57, a price-to-earnings-growth ratio of 2.50 and a beta of 0.95. The firm’s 50 day moving average is $196.45 and its 200 day moving average is $214.10.

Danaher (NYSE:DHR) last posted its earnings results on Tuesday, April 21st. The conglomerate reported $2.06 earnings per share for the quarter, topping analysts’ consensus estimates of $1.94 by $0.12. Danaher had a net margin of 14.89% and a return on equity of 10.91%. The firm had revenue of $5.95 billion for the quarter, compared to analyst estimates of $6 billion. During the same period in the previous year, the firm posted $1.88 EPS. The company’s revenue for the quarter was up 3.7% compared to the same quarter last year. Danaher has set its FY 2026 guidance at 8.350-8.550 EPS. Equities research analysts forecast that Danaher will post 8.4 earnings per share for the current fiscal year.

Insider Activity

In related news, EVP Gregory M. Milosevich sold 1,320 shares of the business’s stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $208.01, for a total transaction of $274,573.20. Following the transaction, the executive vice president owned 5,099 shares in the company, valued at $1,060,642.99. The trade was a 20.56% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 10.80% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Elevated Capital Advisors LLC acquired a new position in shares of Danaher during the 4th quarter valued at $26,000. Hilton Head Capital Partners LLC acquired a new position in shares of Danaher during the 4th quarter valued at $27,000. Clal Insurance Enterprises Holdings Ltd lifted its position in shares of Danaher by 71.6% during the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 127 shares of the conglomerate’s stock valued at $29,000 after acquiring an additional 53 shares during the period. JPL Wealth Management LLC acquired a new position in shares of Danaher during the 3rd quarter valued at $25,000. Finally, WFA of San Diego LLC acquired a new position in shares of Danaher during the 2nd quarter valued at $26,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Key Stories Impacting Danaher

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Q1 EPS beat and slight raise to FY EPS range — Danaher beat non‑GAAP EPS estimates ($2.06 vs. consensus) and nudged full‑year adjusted EPS guidance higher, which supports earnings visibility. Earnings Call Highlights
• Positive Sentiment: Bioprocessing momentum and M&A strategy remain drivers — management highlighted strength in bioprocessing and the acquisition pipeline as long‑term growth levers. Q1 Deep Dive
• Neutral Sentiment: Large euro‑denominated senior‑notes offering (~€2.98B net proceeds) — the deal finances operations and transactions but increases liabilities; market reaction depends on how proceeds are used. Notes Offering
• Neutral Sentiment: Masimo acquisition: longer‑term optionality vs. near‑term integration/earnings pressure — analysts note the deal adds strategic upside but may weigh on near‑term returns and capital allocation. Masimo Analysis
• Negative Sentiment: $172.5M shareholder settlement over post‑pandemic demand disclosures — a material cash charge and reputational headwind that increases near‑term litigation/expense risk. Settlement Report
• Negative Sentiment: Revenue miss and Diagnostics softness weighed on the print — core revenue growth was modest and Diagnostics showed weakness (lighter respiratory season at Cepheid), which undercut the EPS beat. Revenue/Segment Notes
• Negative Sentiment: Multiple analyst price‑target cuts (Morgan Stanley, JPMorgan, Wells Fargo, Guggenheim, UBS among others) — downgrades and lower targets increase downside pressure and reduce near‑term analyst support. Morgan Stanley PT Cut

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.